Achilles Therapeutics ACHL Stock
Achilles Therapeutics Price Chart
Achilles Therapeutics ACHL Financial and Trading Overview
| Achilles Therapeutics stock price | 0.79 USD |
| Previous Close | 0.99 USD |
| Open | 1.02 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 4000 |
| Day's Range | 0.98 - 1.02 USD |
| 52 Week Range | 0.75 - 3.45 USD |
| Volume | 52.85K USD |
| Avg. Volume | 143.72K USD |
| Market Cap | 40.12M USD |
| Beta (5Y Monthly) | 0.927152 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.8 USD |
ACHL Valuation Measures
| Enterprise Value | -110739320 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.80999994 |
| PEG Ratio (5 yr expected) | -0.22 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.21669246 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.652 |
Trading Information
Achilles Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.927152 |
| 52-Week Change | -58.99% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.45 USD |
| 52 Week Low | 0.75 USD |
| 50-Day Moving Average | 0.94 USD |
| 200-Day Moving Average | 1.44 USD |
ACHL Share Statistics
| Avg. Volume (3 month) | 143.72K USD |
| Avg. Daily Volume (10-Days) | 62.59K USD |
| Shares Outstanding | 40.94M |
| Float | 17.9M |
| Short Ratio | 0.14 |
| % Held by Insiders | 5.96% |
| % Held by Institutions | 61.38% |
| Shares Short | 19.03K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.050% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -17.69% |
| Return on Equity (ttm) | -31.58% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -67022000 USD |
| Net Income Avi to Common (ttm) | -71327000 USD |
| Diluted EPS (ttm) | -1.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 158.46M USD |
| Total Cash Per Share (mrq) | 3.87 USD |
| Total Debt (mrq) | 7.6M USD |
| Total Debt/Equity (mrq) | 4.11 USD |
| Current Ratio (mrq) | 10.323 |
| Book Value Per Share (mrq) | 4.523 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56753000 USD |
| Levered Free Cash Flow (ttm) | -43830376 USD |
Profile of Achilles Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | 245 Hammersmith Road |
| ZIP | W6 8PW |
| Phone | 44 20 8154 4600 |
| Website | https://www.achillestx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 234 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Q&A For Achilles Therapeutics Stock
What is a current ACHL stock price?
Achilles Therapeutics ACHL stock price today per share is 0.79 USD.
How to purchase Achilles Therapeutics stock?
You can buy ACHL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Achilles Therapeutics?
The stock symbol or ticker of Achilles Therapeutics is ACHL.
Which industry does the Achilles Therapeutics company belong to?
The Achilles Therapeutics industry is Biotechnology.
How many shares does Achilles Therapeutics have in circulation?
The max supply of Achilles Therapeutics shares is 44.65M.
What is Achilles Therapeutics Price to Earnings Ratio (PE Ratio)?
Achilles Therapeutics PE Ratio is now.
What was Achilles Therapeutics earnings per share over the trailing 12 months (TTM)?
Achilles Therapeutics EPS is -1.74 USD over the trailing 12 months.
Which sector does the Achilles Therapeutics company belong to?
The Achilles Therapeutics sector is Healthcare.
Achilles Therapeutics ACHL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}